Point72 Asset Management’s Neurogene NGNE Stock Holding History

Point72 Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-200,000	Closed	-$2.34M	–	2471
2025 Q1	$2.34M	Buy	+200,000	New	+$3.47M	0.01%	1197

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management's NGNE Position: Q4 2025 in Review

Point72 Asset Management sold out of Neurogene (NGNE) in Q4 2025, closing a stake of 7,669 shares — an estimated $133K sold.

Point72 Asset Management first reported a position in NGNE in Q4 2017 and held it in 20 quarters. The position peaked at $16.9M in Q4 2020. 93 funds tracked by Wall St. Rank hold NGNE as of Q4 2025.

Point72 Asset Management reported no remaining Neurogene position as of Q4 2025 after selling out during the quarter.
Point72 Asset Management sold 7,669 Neurogene shares in Q4 2025, an estimated $133K.
Point72 Asset Management first reported a position in Neurogene in Q4 2017 and held it in 20 quarters.
Point72 Asset Management's Neurogene position peaked at $16.9M in Q4 2020.
93 funds tracked by Wall St. Rank held Neurogene as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.